glp-1 elevated liver enzymes Multiple target tissue effects of analogues on non-alcoholic fatty disease (NAFLD) and non-alcoholic steatohepatitis (NASH) Glucagon-like peptide (GLP)-1 and GLP-2

Considering the effects of TNF on L cells and data from animal models, indicating that impaired glucose tolerance following high-fat diet-induced obesity can be ameliorated by anti-TNF therapy (95), one might expect a significant impact of anti-TNF treatment on glucose metabolism

The overlap is almost complete

One of the best ways to tackle this is by working closely with a medical professional and making thoughtful dose adjustments

Here is what the clinical evidence consistently shows: Significant, sustained weight loss The STEP clinical trials for semaglutide showed average weight loss of 14.9% of body weight over 68 weeks more than double the typical result from traditional dieting programs

As such, postprandial secretion of GIP, GLP-1, and GLP-2 inhibits bone resorption and/or promotes bone formation, representing a gut-bone axis